Johnson & Johnson: The Dividend King Is Back

Nudphon Phuengsuwan Introduction I started covering Johnson & Johnson (NYSE:JNJ) in September of last year, when the stock became interesting again, as spin-off and lawsuit headlines provided several buyable corrections. As we can see below, I have written about this company three times. All of my calls are profitable - yet not by a lot. My most recent article was published on March 28, when I focused on its transition to high-growth healthcare markets. Since then, shares have returned 3.5%, lagging the 6% ...